Gert De Meerleer, MD, PhD, of the Ghent University Hospital, Ghent, Belgium, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. He covers the key areas of research currently being addressed by the prostate cancer radiotherapy community; including an update on the BART study, using immunotherapy in combination with radiotherapy, proton beam therapy.
Well, in prostate cancer, I think the key research area that we are now developing is one, go for stereotactic body radiotherapy for prostate cancers too. This is mainly done in United States and Canada. We are mainly focusing on new indications. For instance, a patient with a heavy lymph node metastatic load, having lot of pelvic lymph nodes, we don’t consider them not curable anymore. We consider them curable and we go for preventive radiotherapy of the lymph nodes in the abdomen. So in the urethroperineal region, because we know once you have pelvic lymph nodes you have a high chance of developing lymph nodes higher up. This is a study we’re doing now clinically, called the BART study. It’s running really well.